From syringes to workflow management systems, healthcare is no stranger to adopting new technologies into standard care. As digital and connected technologies continue to stake their claim in the industry, the last few years have seen the rise of a new type of health technology product — one that promises measurable health outcomes validated by traditional clinical trials.
“You had a little...
As opioid abuse continues to make impact in the US, more and more tech-driven answers to the drug crisis are springing up that aim to reduce patients’ reliance on prescription opioids. Just yesterday, behavioral health therapy app maker 2Morrow threw its hat into the ring with the announcement that its services now include a digital chronic pain management program.
Much like the company’s other...
Digital smoking cessation company 2Morrow has partnered with GlaxoSmithKline, makers of Nicoderm patches, to offer the company’s Nicoderm CQ Patch to smokers who complete 2morrow’s cessation program.
2Morrow’s smoking cessation app, called SmartQuit, is based on acceptance and commitment therapy, or an ACT-based program, that "focuses on increasing one’s willingness to accept the physical, mental...
The National Cancer Institute has awarded Jonathan Bricker, a behavioral scientist and faculty member at Fred Hutchinson Cancer Research Center, with a five-year, $3.1 million grant to conduct a randomized controlled trial of SmartQuit, a smoking-cessation app.
SmartQuit is based on acceptance and commitment therapy, or an ACT-based program, that "focuses on increasing one’s willingness to accept...
Seattle-based behavior change company 2Morrow has launched an app, called SmartQuit, that aims to help smokers quit.
2Morrow partnered with the Fred Hutchinson Cancer Research Center to create the app. In October, 2Morrow published a randomized control trial of 196 participants and found that users of SmartQuit were 2.5 to 3 times more likely to quit than those who try to quit on their own. The...
